12:00 AM
 | 
Jan 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tuberculosis vaccine: Phase II started

Intercell said Statens Serum Institut (Copenhagen, Denmark) began a double-blind, South African and Tanzanian Phase II trial to evaluate 2 doses of H1IC in HIV-infected patients. The European and Developing...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >